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RESEARCH ARTICLE
Gastrointestinal Stromal Tumors: A Clinicopathologic and Risk
Stratification Study of 255 Cases from Pakistan and Review
of Literature
Nasir Ud Din*, Zubair Ahmad, Huma Arshad, Romana Idrees, Naila Kayani
Abstract
Purpose: To describe the clinicopathological features of gastrointestinal stromal tumors (GIST) diagnosed in
our section and to perform risk stratification of our cases by assigning them to specific risk categories and groups
for disease progression based on proposals by Fletcher et al and Miettinen and Lasota. Materials and Results:
We retrieved 255 cases of GIST diagnosed between 2003 and 2014. Over 59% were male. The age range was
16 to 83 years with a mean of 51 years. Over 70% occurred between 40 and 70 years of age. Average diameter
of tumors was 10 cms. The stomach was the most common site accounting for about 40%. EGISTs constituted
about 16%. On histologic examination, spindle cell morphology was seen in almost of 85% cases. CD117 was the
most useful immunohistochemical antibody, positive in 98%. Risk stratification was possible for 220 cases. Based
on Fletcher’s consensus proposal, 62.3 gastric, 81.8% duodenal, 68% small intestinal, 72% colorectal and 89%
EGISTs were assigned to the high risk category; while based on Miettinen and Lasota’s algorithm, about 48%
gastric, 100% duodenal, 76% small intestinal, 100% colorectal and 100% EGISTs in our study were associated
with high risk for disease progression, tumor metastasis and tumor related death. Follow up was available in
95 patients; 26 were dead and 69 alive at follow up. Most of the patients who died had high risk disease and
on average death occurred just a few months to a maximum of one to two years after initial surgical resection.
Conclusions: Epidemiological and morphologic findings in our study were similar to international published
data. The majority of cases in our study belonged to the high risk category.
Keywords: Gastrointestinal stromal tumor - extra gastrointestinal tumor - risk stratification - Pakistan
Asian Pac J Cancer Prev, 16 (12), 4873-4880

Introduction
Gastrointestinal stromal tumors (GISTs) are a
heterogeneous group of tumors which comprise the
most common primary mesenchymal tumors of the
gastrointestinal tract (GIT) and occur throughout the
GIT from esophagus to rectum (Rubin, 2006; LeiglAtzwangar, et al., 2012). The commonest site for GISTs is
stomach (approximately 60%) followed by small intestine
(excluding duodenum) (Nilsson et al., 2005; Miettinen et
al., 2010). About 85-90% GISTs harbor a mutation of KIT
(CD117), a tyrosine kinase receptor which is normally
expressed by the ‘pacemarker’ interstitial cells of cajal
located in the wall of the gut. These cells coordinate the
autonomic nervous system of the gut and the smooth
muscle cells to regulate motility and peristalsis. Most
GISTs therefore originate in the submucosa or muscularis
propria. The remaining 5 to 15% GISTs contain PDGFRA
activity mutations (Heinrich et al, 2002; Hornick and
Fletcher, 2004). The KIT mutation results in the activation
of the Tyrosine kinase receptor allowing the detection of
KIT (CD117) mutation by immunohistochemistry and

helps in confirming the histologic diagnosis of GIST
(Heinrich et al., 2002; Coindre et al., 2005; Zhang et al.,
2009; Miettinen et al., 2010). Most patients are elderly,
median age ranges between 58 and 66 years (Coindre et al.,
2005; Tryggvason et al., 2005; Cao et al., 2010; Miettinen
et al., 2010). However, no definite gender predilection
has been reported. Histologically, most tumors in all
sites show a spindle cell appearance (75 to 80%), while
epithelioid cell or mixed morphology is seen in minority
of cases (Coinder et al., 2005; Miettenin and Lasota, 2006;
Miettenin et al., 2010). Small intestinal GISTs are twice as
likely to behave as clinically malignant tumors compared
to gastric GISTs, while most colorectal GISTs are very
aggressive and advanced tumors with a poor prognosis
(Mittenin et al., 2010a; 2010b).
GISTs can also occur outside the GIT mainly in the
omentum, mesentery and retroperitoneum where they
need to be distinguished from other mesenchymal tumors,
especially from benign and malignant smooth muscle
tumors (Reith et al., 2000).
The most important prognostic factors on the basis
of which GISTs are categorized into distinct prognostic
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groups are tumor size and number of mitoses per 50
high power fields (HPFS) (Miettenin et al., 2010). The
consensus proposal by Fletcher et al. (2002) combined
these two (size and mitotic activity) to divide GISTs into
risk categories, while Miettenin and Lasota also added the
anatomic location to provide comprehensive information
about the prognosis (Miettenin and Lasota, 2006).
The aim of our study was to present the epidemiologic
data of our cases, describe the morphologic (including
Immunohistochemical) features, and perform risk
stratification by assigning our cases into specific risk
categories and groups based on both the consensus
proposal (Fletcher et al., 2002) and the more elaborate risk
prediction algorithm (Miettinen and Lasota, 2006). Follow
up, where available, was taken and recorded.

Materials and Methods
A total of 255 cases (stomach, duodenum, small
intestine, colorectal and extra gastrointestinal) diagnosed
in the Section of Histopathology, Aga Khan University
Hospital, Karachi between the years 2003 and 2014 were
included in the study. Clinical data such as age, gender,
tumor location, tumor size, signs and symptoms and follow
up were recorded. Histological features including spindle
cell or epithelioid or mixed pattern and mitotic activity per
50 HPFs were noted. Immunohistochemical reactivity to
the following antibodies was noted: CD117, CD34, DOG
Table 1. Decade Wise Age Distribution of our Cases
(n=255)
S No.

Decade

Number

Percentage%

1
2
3
4
5
6
7
8

11-20
21-30
31-40
41-50
51-60
61-70
71-80
>80

2
13
33
58
59
62
25
3

0.80%
5.10%
12.90%
22.70%
23.10%
24.30%
9.80%
1.20%

Table 2. Site Wise Distribution of our Cases (n=255)
S No.

Site

1
2
3
4
5
6
7
8
9

Esophagus
Stomach
Duodenum
Jejunum
Ileum
Colorectum
Mesentery
Retroperitoneum
Omentum

Number
1
117
14
22
34
26
23
10
8

Percentage%
0.40%
45.90%
5.50%
8.60%
13.30%
10.20%
9.10%
3.90%
3.10%

1, Anti- Smooth muscle Actin (ASMA) and S100 protein.
Risk stratification was performed using tumor location,
tumor size and mitotic activity / 50 HPFs, and the cases
were assigned to specific risk categories and groups.
Statistical analysis was performed using SPSS 19.0
version.

Results
A total of 255 cases were included. Age of the patients
ranged from 16 to 83 years with mean and median age of
51 and 52 years respectively. The decade wise distribution
is shown in Table 1. As shown in this table, over 70%
were between 40 and 70 years of age. Out of 255, 151
(59.2%) patients were males, and 104 (40.8%) were
females. Male: female ratio was 1.4:1. Of the 255 cases,
35 (13.7%) were small core biopsies while 220 (86.3%)
were resection specimens. The size of the tumors ranged
from 2.0 cms to 26 cms with an average size of 10 cms
in the largest dimension.
Stomach was the commonest site in our series
followed by the small intestine. The site wise breakup is
shown in Table 2. Almost 46% of all cases were located
in the stomach while over 27% were located in the small
intestine. Extra GI GISTs comprised 41 cases (16.10%).
Grossly, majority of tumors were submucosal or
intramural, nodular bulging masses, many with central
ulceration. Some were polypoid and protruded into the
gastric lumen (Figure 1A,B). Majority of our small
intestinal and colorectal GISTs were polypoid with
protrusion into the lumen and were less commonly
intramural.
Out of 255 cases, 216 (84.7%) showed spindle cell
morphology, 32 (12.5%) showed epithelioid morphology,
while 7 cases (2.7%) were mixed (Figure 2A,B).
Immunohistochemistry was performed on most
cases (Figure 3A,B). The antibodies employed and
immunohistochemistry results are summarized in Table
3. The antibody DOG1 was acquired in 2013. Hence, this
antibody was used only in the recently diagnosed cases.
Risk stratification and assigning of cases into specific
risk categories and groups was done based on the studies
(Fletcher et al., 2002; Miettinen and Lasota, 2006). Risk
stratification was not possible on 35 cases as these were
small core biopsies. It was thus performed on 220 cases.
These included 98 out of 117 cases of gastric GIST, 50
out of 56 cases of jejunal and ileal GISTs, 11 out of 14
cases of duodenal GISTs, 25 out of 27 cases of colorectal
GISTs, and 36 out of 41 cases of extra GI GISTs. The
findings are shown in Tables 4 and 5.
Follow up was available in 95 out of 220 cases. Of
these 95 patients, 69 are alive, while 26 patients died.

Table 3. Immunohsitochemical Profiles of Cases in our Study (n=255)
S No.

Immunohistochemical antibody

Positive

Focal positive

Negative

Not performed

1
2
3
4
5

CD 117
CD 34
DOG 1
Smooth Muscle Actin (ASMA)
S 100 protein

242 (94.9%)
169 (70.4%)
18 (72.0%)
67 (29.4%)
64 (30.3%)

8 (3.1%)
14 (5.8%)
2 (8%)
45 (19.7%)
29 (13.7%)

5 (2%)
57 (23.8%)
5 (20%)
116 (50.9%)
118 (56%)

--15
230*
27
44

*acquired in 2013
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Table 4. Risk Stratification. Assignment of Cases in our Series into Risk Categories Based on Fletcher et al’s
Proposal(18) (n=220)
S. No.
1
2
3
4
5
6
7

Site
Stomach
Duodenum
Jejunum + Ileum
Colorectum
Mesentery
Retroperitoneum
Omentum

Number

Very Low Risk *

Low Risk **

Intermediate Risk ***

High Risk ****

98
11
50
25
19
13
4

3 (3.1%)
-------------

17 (17.3%)
--5 (10%)
2 (8%)
-------

17 (17.3%)
2 (18.2%)
11 (22%)
5 (20%)
1 (5.3%)
3 (23.1%)
---

61 (62.3%)
9 (81.8%)
34 (68%)
18 (72%)
18 (94.7%)
10 (76.9%)
4 (100%)

*> 2 cms, > 5 M / 50 HPF; **2-5 cms, > 5 M / 50 HPF; ***<5 cms, 6-10 M / 50 HPF; or 5-10 cms, < 5 M / 50 HPF; ****>5 cms, > 5 M /50 HPF;
or > 10 cms, any no. of mitoses; or any size, > 10 M /50 HPF

Table 5. Risk Stratification. Assignment of Cases in our Series into Risk Groups Based on Miettinen and Lasota’s
Algorithm(14) (n=220)
S. No. Site
1
2
3
4
5

Number Group 1

Stomach
Duodenum
Jejunum+Ileum
Colorectum
EGISTs

Group 2

Group 3a

Group 3b

Group 4

98
5 (5.1%) 15 (15.3%) 10 (10.2%) 8 (8.2%)
--11			
1 (9.1%)			
50
--5 (10%)
7 (14%) 13 (26%)
--25
----2 (8%)
3 (12%)
--36
----2 (5.5%) 6 (16.7%)
---

Group 5

Group 6a

13 (13.3%) 20 (20.4%)
1 (9.1%) 1 (9.1%)
4 (8%)
7 (14%)
7 (28%)
6 (24%)
2 (5.5%) 3 (8.3%)

Group 6b
27 (27.5%)
8 (72.7%)
14 (28%)
7 (28%)
23 (63.9%)

*Group 1:> 2 cms, < 5 M / 50 HPF; Group 2: 2-5 cms, < 5 M / 50HPF; Group 3a:5-10 cms, < 5 M / 50HPF; Group 3b:>10 cms, < 5 M / 50HPF;
Group 4:<2 cms, > 5 M / 50HPF; Group 5:2-5 cms, > 5 M / 50HPF; Group 6a:5-10 cms, > 5 M / 50HPF; Group 6b:> 10 cms, > 5 M / 50HPF

Table 6. Data of Patients who were Dead at Follow Up (n=26)
S. No.

Site

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Retroperitoneum
Jejunum
Stomach (a)
Stomach
Stomach
Colorectum
Jejunum (b)
Duodenum
Retroperitoneum (c)
Colorectum (d)
Stomach (e)
Colorectum (f)
Jejunum (g)
Retroperitoneum (h)
Stomach (i)
Stomach
Mesentery
Mesentery
Colorectum
Ileum
Stomach (j)
Stomach (k)
Duodenum (l)
Stomach (m)
Retroperitoneum (n)
Stomach

Risk Category

Group

Gleevec Status

Year of Surgery

Year of Death

High
High
High
High
High
High
Moderate
High
High
High
High
High
High
High
Moderate
High
High
High
High
High
High
Very Low
High
Moderate
High
High

6b
6b
6b
6a
6b
6a
3a
6a
6b
6b
6b
6b
6b
6b
5
6b
6b
6a
6b
6a
6b
2
6a
5
6b
6a

No
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
Yes
Yes
No
Yes
No
No
No
No
No
Yes
No
No
Yes
Yes
Yes
Yes

2004
2004
2004
2005
2005
2006
2006
2006
2008
2009
2009
2009
2009
2009
2010
2010
2011
2011
2011
2011
2012
2012
2012
2013
2013
2013

2006
2007
2006
2005
2007
2006
2012
2006
2008
2011
2009
2011
2009
2010
2011
2010
2012
2011
2013
2012
2012
2012
2012
2014
2013
2014

* Note: Additional information available: (a) Metastasis to kidney and heart, died in 2006; (b) Took Gleevec continuously, no history of recurrence
or metastases; (c) Died immediately after surgery; (d) Took Gleevec regularly, died during surgery for excision of recurrent tumor; (e) Took Gleevec
regularly until death seven months after surgery; (f) Took Gleevec regularly until death two years after surgery; (g) Died immediately after surgery;
(h) Took Gleevec regularly until death six months after surgery; (i) Died of liver failure in 2011 (had chronic Hepatitis C); (j) Died soon after surgery;
(k) Very low risk disease, died three months after surgery from widespread metastases of concomitant colorectal adenocarcinoma; (l) Died four
months after surgery, took Gleevec regularly; (m) Took Gleevec regularly, died about one year after surgery, possibly due to some unrelated cause;
Took Gleevec regularly until death four months after surgery

Of the latter, 1 patient had a very low risk gastric GIST.
However, he had a concomitant gastric adenocarcinoma
with positive lymph nodes, and died as a result of
complications secondary to the adenocarcinoma. Of

the remaining 25 patients, 22 had high risk while 2 had
moderate risk disease. The disease was located in the
stomach in 10 cases, small intestine (ileum and jejunum)
in 4 cases, duodenum in 2 cases and colorectum in 4

Asian Pacific Journal of Cancer Prevention, Vol 16, 2015

4875

Nasir Ud Din et al

Table 7. Data of Patients who were Alive at Follow Up-Site wise Breakup (n=69)
Year Resected
Treated with
		Gleevec

Risk Category

Site

No. of 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Yes No V. low low Inter- High Recur- MetaCases														
risk risk mediate risk rence stases
																	risk
Esophagus
1
Stomach
32
Duodenum
1
Small Intestine 19
(Jejunum+Ileum)
Colorectum
10
EGISTs
6

1
-

2

1

-

1

1
1
3

4
6

1
9
2

5
2

12
2

-

1
23
1
13

9
6

2
-

1
4
1

9
5

17
1
13

1
1

4
1

-

-

-

-

-

1
1

3
1

2
3

3
-

1
1

-

8
6

2
-

-

-

5
3

5
3

2
-

1
-

of these 69 patients are given in Table 7.

Discussion

Figure 1. A) Gross Appearance of GIST of Stomach
Protruding into the Lumen; B) GIST of Stomach with
a Fleshy Cut Surface

Figure 2. A) Spindle cell GIST Arranged in Fascicles.
B) Sheets of Epithelioid Cells with Eosinophilic
Cytoplasm in Epithelioid GIST

Figure 3. CD117 (A) and DOG 1 (B) Positivity in GIST
cases, while 6 cases represented EGISTs. Out of the 26
patients, 15 had been treated with Gleevec, while 11 did
not receive this treatment. The details of these 26 patients
are given in Table 6.
Out of the 69 patients who are still alive, 47 had high
risk disease, 15 had intermediate risk, 5 had low risk and 2
patients had very low risk disease. Of these 69 patients, 4
patients had one or more recurrences and 6 had metastatic
disease at the time of follow up. The disease was located
in the stomach in 32 out of 69 cases, in the small intestine
(ileum and jejunum) in 19 cases, duodenum in 1 case,
colorectum (including anal region) in 10 cases, and
esophagus in 1 case, while EGISTs accounted for 6 cases.
Out of the 69 patients, 52 had been treated with Gleevec,
while 17 patients did not receive this treatment. The details
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In 2013, we published an epidemiological and
histological perspective of diseases of the gastrointestinal
tract in Pakistan (Ahmad et al., 2013). In the current article,
an epidemiological, histological and risk stratification
perspective of GIST is presented.
As shown in the results, mean age was 51 years and
the highest number of cases were diagnosed in the fifth,
sixth and seventh decades (Table 1). The mean age is much
lower in our series than reported in Western and even Asian
literature where mean ages of gastric and small intestinal
GISTs have varied from 58 to 70 years (Coindre et al.,
2005; Tryggvason et al., 2005; Cao et al., 2010; Miettinen
et al., 2010; Wang et al., 2013). GISTs in all locations
occur in the elderly, less than 10% gastric GISTs occur
in patients below 40 years of age (Miettinen and Lasota,
2006). In our study, almost 19% GISTs occurred below
the age of 40 years (Table 1). Studies have shown no
gender predilection, although some studies demonstrate
a mild male predominance i.e. 52 to 55% in GISTs in all
locations (Cao et al., 2010; Miettenin et al., 2010). In our
study, over 59% patients were males. The average size of
tumors in our study was 10 cms and size ranged from 2 to
26 cms. Various studies have reported sizes ranging from a
few millimeters to greater than 20 cms for small intestinal,
and a few millimeters to greater than 40 cms for gastric
GISTs (Miettinen and Lasota, 2006). In the largest series
of gastric GISTs published (Miettinen et al., 2005), the
mean size for gastric GISTs was 6 cms. In two separate
studies, from Iceland and China, mean tumor size was 4.6
cms and 7.02 cms respectively (Tryggvason et al., 2005;
Cao et al., 2010). Symptoms in our cases were variable;
the commonest were vague abdominal pain, abdominal
mass, heart burn, bleeding per rectum, hematemesis,
anemia etc. Grossly, majority of our gastric tumors were
submucosal or intramural, nodular bulging masses, many
with central ulceration. Some were polypoid and protruded
into the gastric lumen. Majority of our small intestinal
and colorectal GISTs were polypoid with protrusion into
the lumen and were less commonly intramural. Similar,
gross appearances have been described by various authors
(Rosai, 2003; Miettenin and Lasota, 2006).
In our series, stomach was the commonest site, (almost
46%), while almost 22% were located in the small intestine
(jejunum and ileum excluding duodenum). If duodenum

is included, over 27% cases were located in the small
intestine (Table 2). According to various international
studies, 59 to 61% GISTs occur in stomach (Nilsson et
al., 2005; Tryggvason et al., 2005; Miettenin et al., 2006),
about 30% in the jejunum and ileum, and 4 to 5% occur
in the duodenum (Miettenin et al.,2003). Colorectal GISTs
comprise 4 to 5% (Miettenin et al., 2006, Cao et al., 2010).
Compared to the international data, location in stomach
and small intestine was slightly less common in our series
while location in colon and rectum was slightly higher.
However, a recent study from Turkey reported tumor
location in the stomach in 45.6% cases, very similar to
our findings (Selcukbiricik et al., 2013).
On histological examination, almost 85% cases
showed spindle cell morphology while cases with
epithelioid morphology comprised over 12%. Various
international studies have reported the epithelioid type to
comprise between 20-25%, with mixed tumors comprising
the remaining 5 to 10% cases (Coinder et al., 2005;
Miettenin et al., 2006; Miettenin et al., 2010).
Immunohistochemically, CD117 was the most useful
antibody, being strong diffuse positive in almost 95%.
CD 34 showed diffuse strong positivity in over 70%. We
have limited experience with DOG1 since we acquired this
antibody only in 2013. It demonstrated diffuse positivity
in 72%. We intend to use DOG1 in all future cases as this
antibody has proved to be a very sensitive and specific
marker for GISTs (Miettenin et al., 2009). Anti-Smooth
Muscle Actin (ASMA) was diffuse or at least focal positive
in about 49% cases, while S100 protein was diffuse or
focal positive in 44% cases (Table 3).
Published Western literature shows that CD117
positivity is seen in 95% (gastric) to 98% (small intestinal)
GISTs, and CD34 positivity in 60-70% GISTs. However,
CD34 positivity varies with positivity seen in 80 to 85%
gastric, 50% small intestinal and 95 to 100% esophageal
and colorectal GISTs. It has been seen that most spindle
cell GISTs shown positivity for CD34 (Coinder et al.,
2005; Miettenin et al., 2005; Miettenin and Lasota, 2006;
Miettenin et al., 2006). A study from China showed CD117
positivity in 94.5% and CD34 positivity in 86.2% cases
(Cao et al., 2010). Another Asian study showed CD117 and
DOG 1 positivity in 90.5% and 84.1% cases respectively
(Sun et al., 2012).
With regard to ASMA and S100 protein, positivity for
the former has been reported in 20% of gastric and 35% of
small intestinal GISTs, while positivity for the latter has
been reported rarely (<1%) in gastric GISTs. However,
positivity for S100 protein has been very variable with
various studies reporting positivity in 14% to 50% cases.
Studies have demonstrated that CD34 expression is not a
significant prognostic factor for gastric and small intestinal
GISTs. However, ASMA expression is a statistically
significant favorable prognostic factor in gastric and
small intestinal GISTs (Tworek et al., 1997; Miettenin
et al., 2005; Miettenin et al., 2006). The prognostic and
predictive potential of immunohistochemical stains in
GIST has been studied but results are conflicting and
inconclusive (Sun et al., 2012; Demir et al., 2013).
Over 16% cases in our series were diagnosed as
extra gastrointestinal GISTs (EGISTs) and most of these
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were high risk (Tables 4&5). While EGISTs definitely
represent bona fide and true GISTs, and demonstrate
CD117 immunohistochemical expression as well as GISTspecific KIT mutations (Rosai et al., 2004; Yamamoto
et al.,2004; Miettenin et al., 2013), their incidence in
most series is extremely low, around 1% (Miettenin and
Lasota, 2006). One study did not find a single convincing
case among 200 cases (Agaimy and Wunsch, 2006).
However, EGISTs comprised 10% of all GISTs in a
study from Korea (Cho et al., 2010). The current concept
is that most so called EGISTs are actually detachments
or metastases from GISTs of primary gastrointestinal
tract origin (Miettenin and Lasota, 2006; Miettenin et
al., 2013). We get a lot of referral cases from all over
Pakistan, a large country with a population of 190 million,
and accurate surgical details or radiological films are not
available in many cases. It is quite possible that many
of the so called EGISTs in our series actually represent
involvement of retroperitoneum, omentum, mesentery
etc by gastrointestinal stromal tumors. Studies have
looked for parameters that can clearly identify bona fide
EGISTs. Matrix metalloproteinases (MMPs), which are
molecules that are implicated in metastasis by various
malignant tumors, have been investigated for their role
in contributing to the ability of EGISTs to metastasize.
A recent study demonstrated that increased MMP-2 and
MMP-9 expression was associated with increased risk of
metastasis and aggressive behavior in E-GISTs (Wang et
al., 2014).
The evaluation of prognosis is essential in GIST.
Every GIST carries a risk and potential for malignant
behavior and there is increasing reluctance to label any
GIST as benign. However, this risk varies from very low
to very high (Coinder et al., 2005; Miettenin et al., 2013).
Earlier studies showed that about 50% primary localized
GISTs relapsed within the first five years (local recurrence
within the peritoneal cavity or liver metastases) while a
much greater percentage of GISTs relapsed within ten
years, and that if relapse occurred, prognosis was almost
invariably poor (Franquemont, 1995; Emory et al., 1999;
DeMatteo et al., 2000). It became increasingly clear that
it was not practically possible to divide GISTs into benign
or malignant categories based on morphology alone
and the emphasis shifted to determining criteria which
could assess the risk of GISTs to behave in a malignant
fashion. Several schemes were developed to define criteria
which can stratify the risk of malignant behavior and by
which GISTs can be assigned to definite risk categories
(low, intermediate, high) or groups (Franquemont, 1995;
Fletcher et al., 2002; Miettenin and Lasota, 2006). Tumor
size and number of mitoses per 50/HPFs emerged as the
major criteria. It also became clear that location was
extremely important, with non-gastric GISTs harboring
a much higher risk for malignant behavior compared to
gastric GISTs of comparable size and mitotic activity
(Tryggvason et al., 2005; Miettenin and Lasota, 2006).
Other histologic factors including cellularity, coagulative
necrosis, mucosal invasion etc have been suggested
(Miettenin et al., 2005; Tryggvason et al., 2005; Miettenin
et al., 2006). Currently, the risk stratification is based on
the consensus proposal (Fletcher et al., 2002) and the risk

Asian Pacific Journal of Cancer Prevention, Vol 16, 2015

4877

Nasir Ud Din et al

prediction algorithm (Miettinen and Lasota, 2006). Based
on these, over 62% of gastric, almost 82% duodenal, 68%
small intestinal (jejunum and ileum), 72% colorectal,
95% mesenteric, 77% retroperitoneal and 100% omental
GISTs in our series belonged to high risk category (Table
4). In a recent study from Turkey which looked at 249
cases, 47% cases belonged to the high risk category
(Selcukbiricik et al., 2013). Other recent studies from Asia
have also risk stratified GISTs based on the above criteria
(Chen et al., 2013). High risk tumors made up 70% and
60% respectively of all cases in two studies from India
(Lakshmi et al., 2010; Ravikumar et al., 2011).
Table 4 also shows that 3% of all gastric GISTs fell
into the very low risk category, while 17.3% each fell into
low risk and intermediate risk categories. Among jejunal
and ileal GISTs, 10% and 22% fell into low risk and
intermediate risk categories respectively, while 8% and
20% colorectal GISTs fell into the low and intermediate
risk categories. Of the so called EGISTs in our series, just
over 5% of mesenteric and 23% retroperitoneal GISTs fell
into the intermediate risk category.
Based on Miettinen and Lasota’s study (Miettinen
and Lasota ,2006), over 5% of gastric GISTs in our study
fell into ’Group 1’ which is not associated with any risk
for progressive disease, tumor metastases and /or tumor
related death. These were the only tumors in our study
which fell in group 1 (Table 1). Over 15% of gastric and
10% of jejunal and ileal GISTs in our study fell into ‘Group
2’ which is associated with very low risk for progressive
disease, metastases and tumor related death for gastric
and low risk for GISTs in all other locations. Just over
10% gastric and 9% duodenal GISTs, 14% small intestinal
(jejunal and ileal), 8% colorectal, and over 5% EGISTs fell
in ‘Group 3a’ which is associated with low risk for gastric
and moderate risk for ileal and jejunal GISTs. Slightly
over 8% gastric, 26% small intestinal (jejunal and ileal),
12% colorectal and almost 17% EGISTs fell in ‘Group 3b’
according to Miettinen’s algorithm. Group 3b is associated
with moderate risk for gastric and high risk for jejunal
and ileal GISTs. Miettinen and Lasota (Miettinen and
Lasota, 2006) combined groups 3a and 3b in duodenal
and colorectal GISTs due to small number of cases and
the ‘Combined group 3’ is associated with high risk for
duodenal and rectal GISTs. No tumor in our study fell
into ‘Group 4’. Over 13% gastric, over 9% duodenal, 8%
small intestinal, 28% rectal and over 5% EGISTs in our
study fell in ‘Group 5’ which is associated with moderate
risk for gastric and high risk for all other locations. Over
20% gastric, over 9% duodenal, 14% jejunal and ileal,
24% colorectal and over 8% EGISTs in our study fell into
‘Group 6a’ which is associated with high risk for gastric as
well as jejunal and ileal GISTs. Over 27% gastric, almost
73% duodenal, 28% small intestinal (jejunal and ileal),
28% colorectal and almost 64% EGISTs in our study
fell into ‘Group 6b’ which is associated with high risk for
gastric as well as Jejunal and Ileal GISTs. Miettinen and
Lasota (Miettinen and Lasota,2006) combined groups 6a
and 6b in duodenal and rectal GISTs due to small number
of cases and the ‘Combined Group 6’ is associated with
high risk for duodenal and colorectal GISTs. Jejunal and
ileal, duodenal and rectal GISTs in groups 5, 6a and 6b, and
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gastric GISTs in groups 6a and 6b all carry a high risk for
progressive disease, metastases and tumor related death.
Gastric GISTs in groups 3b and 5 and jejunal and ileal
GISTs in group 3a carry a moderate risk for progressive
disease; gastric GISTs in group 3a, jejunal and ileal,
duodenal and colorectal GISTs in group 2 carry a low
risk for progressive disease; while gastric GISTs in group
2 carry a very low risk for progressive disease, tumor
metastasis and tumor related death (Miettinen and Lasota,
2006). Earlier studies by Miettinen et al (Miettinen et al.,
2005; Miettinen et al., 2006) showed that about 16%, 55%
and 86% of gastric GISTs in groups 5, 6a and 6b; 73%,
85% and 90% of jejunal and ileal GISTs in groups 5, 6a
and 6b; 50% duodenal and 52% rectal GISTs in group 5;
while 86% duodenal and 71% rectal GISTs in combined
group 6 developed progressive disease, tumor metastases
and tumor related death.
Based on Fletcher et al.’s consensus approach (Fletcher
et al.,2002), about 38% gastric GISTs in our study (Tables
4 & 5) were assigned to the very low, low and intermediate
risk categories while 62% are assigned to the high risk
category. Using the more elaborate algorithm, developed
by Miettinen and Lasota (Miettinen and Lasota,2006) ,
about 52% of gastric GISTs in our study were assigned
groups 1, 2, 3a, 3b and 5 which are associated with no
risk (group 1), very low risk (group 2), low risk (group
3a) and moderate risk (group 3b and 5) and the remaining
48% gastric GISTs were assigned groups 6a and 6b which
are associated with high risk for disease progression,
metastasis and tumor related death (Fletcher et al.,
2002). About 18% of duodenal GISTs in our series were
assigned the intermediate risk category while 82% were
assigned the high risk category. However, all our duodenal
GISTs were assigned to groups 3, 5 and 6 all of which
are associated with high risk in duodenal GISTs. About
10% of small intestinal (jejunal and ileal) GISTs were
assigned to the intermediate risk, and 68% were assigned
to the high risk category. However, based on Miettinen
and Lasota’s proposal (Miettinen and Lasota, 2006), 10%
small intestinal GISTs in our study were assigned group
2 (low risk), 14% were assigned group 3a (moderate
risk) and the remaining 76% were assigned groups 3b,
5, 6a and 6b all of which are associated with high risk
for disease progression in jejunal and ileal GISTs. Based
on Fletcher’s proposal [18], 8% and 72% of colorectal
GISTs were assigned to the low risk and high risk category
respectively. Based on Miettinen’s algorithm (Miettinen
and Lasota,2006), all colorectal GISTs were assigned
groups 3, 5 and 6 all of which are associated with high
risk in colorectal GISTs.
About 11% EGISTs in our study were assigned to the
intermediate risk and 89% to high risk category, but all
were assigned groups 3, 5 and 6 which are associated with
high risk of tumor progression in EGISTs.
The primary treatment of GISTs is surgical excision
with adequate negative tumor margins. All patients in our
series underwent resection, with negative surgical margins
in all but 4 patients.
Although surgical excision is the mainstay of therapy
for GISTs, targeted therapy with Imatinib mesylate
(Gleevec) which binds to KIT and inhibits intracellular

signaling, has shown spectacular results especially in
patients with unresectable, recurrent and even metastatic
tumors (Mechtersheimer et al.,2004). Although there
is still no agreement on whether it should be given in
the adjuvant or neoadjuvant setting, some authorities
now recommend adjuvant treatment if the chances of
recurrence are greater i.e. large tumor size, location
other than gastric, high mitotic rate etc. Treatment is
recommended for at least a year after surgery, while
for tumors which are highly likely to recur, treatment is
recommended for up to three years after surgery. A recent
study showed that preoperative Imatinib was associated
with improved surgical margins while perioperative
Imatinib resulted in improved disease free and overall
survival in rectal GISTs (Jakob et al., 2013). A study
from India demonstrated the role of Imatinib in adjuvant
and therapeutic settings and reported that responses
were durable and most patients tolerated the drug well
at clinically effective doses (Kapoor et al., 2013). Newer
drugs, such as sunitinib are also coming up and may be
effective in patients who become resistant to gleevec. A
study by Li et al. on Chinese patients with gleevec resistant
or intolerant GISTs showed that Sunitinib was effective
in such patients and they tolerated this drug well (Li et
al., 2012). Similar findings were reported by Yoon et al in
Korean patients (Yoon et al., 2012). In turn, even newer
drugs which may be useful in patients with advanced
tumors and resistance to both imatinib and sunitinib are
also coming up fast (DeMatteo et al., 2009; Blay et al.,
2010; Demetri et al., 2013; Joensuu et al., 2013). Recently,
a study from China demonstrated that surgical removal
of metastatic lesions of GISTs in patients who were
also receiving and responding to Imatinib improved the
outcome in such patients (Du et al., 2014). Thus the role
of surgery in patients with recurrent or metastatic GISTs
who were responding to Imatinib is currently a subject
for additional research.
A study by Sevinc et al. investigated cyclooxygenase 2
(COX-2) expression in GIST. Their findings demonstrated
that use of Cox-2 inhibitors, with or without Tyrosine
Kinase inhibitors, may be helpful in the adjuvant setting
in preventing or delaying recurrence (Sevinc et al., 2010).
Follow up was available in 95 cases out of which 69
patients are alive and 26 patients died. A glance at table 6
shows that most of these patients, irrespective of location,
had high risk tumors. Most of these patients lived on
average a few months to one to two years after initial
surgical resection. Only one patient, with an intermediate
risk tumor in the jejunum, survived for 6 years after
resection. It appears that at least for most of these 26
patients who died, Gleevec status apparently did not
significantly alter the clinical course. However, in a poor
country like Pakistan, where compliance issues are very
important, it is quite possible that poor response to Gleevec
may in reality represent lack of compliance rather than
failure of response to the drug. Of the 69 patients who are
alive, the majority have high risk tumors irrespective of the
location. Most of these patients had resections in the last
four to five years (Table 7). As shown in Table 7, 3 patients
with small intestinal GISTs, one with a low risk and two
with intermediate risk tumors, have survived since their
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initial resection in 2005 and 2006. Conversely, 4 patients
with high risk gastric GISTs who were initially operated
in 2010 and later have developed early metastatic disease.
As most of the 69 patients who are alive underwent initial
resection relatively recently i.e. over the last four to five
years (many as late as 2013), it may be too early yet
to assess the impact of Gleevec therapy on the clinical
course of these patients. A study from India showed that
preoperative Gleevec resulted in enough downstaging in
patients with locally advanced GIST allowing resection
with negative margins in a fairly good proportion of such
patients (Ashraf et al., 2011). Similarly, a recent study
from Taiwan demonstrated that the outcome for patients
with GIST has improved significantly with the availability
and wider use of Gleevec (Chiang et al., 2014).
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